VKTX

Viking Therapeutics

Last Updated:

Q3 '20

Price

quotes and stock data delayed 15 minutes

Cash

$255.3M

Burn Rate (Qtr)

-$9.3M

Company Profile

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

VK0612

Type 2 Diabetes

Phase 2 TBA

TBD

VK5211 (SARM)

Hip Fracture, Muscle Wasting

Phase 3 TBA

TBD

VK2809

NASH

Phase 2

TBD

VK2809

Non-Alcoholic Fatty Liver Disease (NAFLD)

Phase 2

TBD

VK1430

High Triglycerides, NASH

Pre-Clinical

TBD

VK0214

X-ALD

Phase 1 (Results)

TBD

Recent Posts

See what the community is saying - click to see full post

VKTX - Presents New Data from Phase 2 Study of VK2809 in Patients with NAFLD and Elevated LDL-C

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon